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Abstract
Summary We compared self-perception of fracture risk with
actual risk among 60,393 postmenopausal women aged
≥55 years, using data from the Global Longitudinal Study of
Osteoporosis inWomen (GLOW).Most postmenopausalwomen
with risk factors failed to appreciate their actual risk for fracture.
Improved education about osteoporosis risk factors is needed.
Introduction This study seeks to compare self-perception of
fracture risk with actual risk among postmenopausal
women using data from GLOW.
Methods GLOW is an international, observational, cohort
study involving 723 physician practices in 17 sites in ten
countries in Europe, North America, and Australia. Partic-
ipants included 60,393 women ≥55 years attended by their
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physician during the previous 24 months. The sample was
enriched so that two thirds were ≥65 years. Baseline
surveys were mailed October 2006 to February 2008. Main
outcome measures were self-perception of fracture risk in
women with elevated risk vs women of the same age and
frequency of risk factors for fragility fracture.
Results In the overall study population, 19% (10,951/58,434)
of women rated their risk of fracture as a little/much higher
than that of women of the same age; 46% (27,138/58,434)
said it was similar; 35% (20,345/58,434) believed it to be a
little/much lower. Among women whose actual risk was
increased based on the presence of any one of seven risk
factors for fracture, the proportion who recognized their
increased risk ranged from 19% for smokers to 39% for
current users of glucocorticoid medication. Only 33% (4,185/
12,612) of those with ≥2 risk factors perceived themselves as
being at higher risk. Among women reporting a diagnosis of
osteopenia or osteoporosis, only 25% and 43%, respectively,
thought their risk was increased.
Conclusion In this international, observational study, most
postmenopausal women with risk factors failed to appreci-
ate their actual risk for fracture.
Keywords Osteoporosis . Postmenopausal . Risk factor .
Women
Introduction
Clinical risk factors associated with an increased probabil-
ity of osteoporosis-associated fractures in postmenopausal
women are well documented, and several interventions
have been shown to lower fracture risk [1–3]. However,
there is evidence that many individuals who have these risk
factors and are candidates for preventive care to reduce the
likelihood of future fractures go unrecognized and untreated
[4, 5]. While responsibility for this gap is assumed to lie
largely within the healthcare system, individuals also need
to recognize and understand the risks that predispose them
to fracture in order to be motivated to both seek medical
care and adhere to recommendations made if effective
prevention strategies are to be successful. Several studies
suggest that under-appreciation of osteoporosis-related
fracture risk may play a role in explaining the evaluation
and treatment gap. In community samples of women from
South Australia, there was a lack of knowledge of
osteoporosis risk factors overall; risk was wrongly self-
perceived to be higher among younger (age 45 to 54 years)
than older (>55) women [6]. In a community-based study
of women with an average age of 60 (85% greater than age
50) from the Southwestern United States, only 16%
perceived themselves to be at higher risk of osteoporosis
compared with 63% who thought their risk was low [7].
Among a group of Canadian patients with recent fragility
fractures, fewer than 50% believed they were at increased
risk of future fractures [8].
To explore the role that patient perceptionsmight play in the
current setting of both under-diagnosis and under-treatment of
those at increased risk of fracture, we assessed self-perceived
risk of fracture among women 55 years of age and older. We
compared perceived risk with self-reported characteristics
known to increase fracture risk, including risk factors utilized
by the FRAX® algorithm (the recently released World Health
Organization 10-year absolute fracture risk assessment tool
[9]), using data from the Global Longitudinal Study of
Osteoporosis in Women (GLOW). Our goals were to gauge
the degree of concordance between perceived and actual risk
and to identify the factors that women most recognized as
placing them at increased fracture risk.
Methods
Setting
GLOW is an observational cohort study that is being
conducted in physician practices in 17 sites in ten countries
(Australia, Belgium, Canada, France, Germany, Italy,
Netherlands, Spain, UK, and USA) in Australia, Europe,
and North America. These sites are located in major
population centers. Clinical investigators at each of the 17
sites constitute the GLOW Scientific Advisory Board and
are responsible for the management of the study. Details of
the study design and methods have been previously
described [10]. In brief, practices typical of each region
were recruited through primary care networks organized for
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administrative, research, or educational purposes or by
identifying all physicians in a geographic area. Physician
networks included regional health system-owned or man-
aged practices, health maintenance organizations, indepen-
dent practice associations, and other primary care practice
networks. Networks established for the purpose of general
medical research were used only if they were not
established exclusively for osteoporosis research and did
not consist primarily of physicians whose primary focus
was academic. Each study site obtained ethics committee
approval to conduct the study in the specific location.
Definitions
Primary care physicians were defined as those who spent
most of their time providing primary healthcare to patients
and included internists, family practitioners, and general
practitioners. If the physician network or study area
included more eligible physicians than were required to
recruit a sufficient number of patients, a random sample of
those physicians within the network or study was invited.
Each practice provided a list of the names and addresses
of women aged 55 years and older who had been attended
by their physician in the past 24 months. Sampling was
stratified by age to ensure that two thirds consisted of
women 65 years of age and older. In each practice, we
recruited from all eligible women 65 and over and from a
random sample of half that number less than 65 years.
Patients were excluded if they were unable to complete the
study survey due to cognitive impairment, language
barriers, institutionalization, or were too ill.
Questionnaire design
Questionnaires were designed to be self-administered and
covered domains that included: patient characteristics and
risk factors, perception about fracture risk and osteoporosis,
medication use (currently taking or ever taken), medical
diagnoses, healthcare use and access, physical activity, and
physical and emotional health status. Where possible, items
from published validated instruments were used, including
the National Health and Nutrition Examination Survey [11],
EuroQol EQ-5D [12], and SF-36 [13] (physical function
component).
Self-reports of personal risk factors included: current
weight and height, parental hip fracture, two or more falls
in the past 12 months, current use of cortisone or
prednisone, diagnosis of rheumatoid arthritis, personal
history of fracture (clavicle, arm, wrist, spine, rib, hip,
pelvis, upper leg, lower leg, and ankle) since age 45,
current cigarette smoking, and consumption of three or
more units of alcohol daily. With the exception of falls,
these risk factors are all included in the FRAX tool [9].
Subjects were considered to be taking antiosteoporosis
medications if they reported current use of alendronate,
calcitonin, estrogen, etidronate, ibandronate, pamidronate,
PTH [1–84], raloxifene, risedronate, strontium ranelate,
teriparatide, tibolone, or zoledronate. Respondents rated
their perceived risk of fracture compared with women of
the same age using a five-point scale that ranged from
“much lower” to “much higher.”
Baseline questionnaires along with invitations to partic-
ipate in the study signed by the local principal investigator
were mailed to all potential subjects. Non-respondents were
followed up with sequential postcard reminders, second
questionnaires, and telephone interviews.
The FRAX tool [9] is a risk assessment survey that
calculates the 10-year probability of hip fracture and the 10-
year probability of major osteoporosis-related fracture
(clinical spine, forearm, hip, or proximal humerus fracture).
It is composed of 11 variables: age, sex, weight, height,
previous fracture as an adult, parental hip fracture, current
cigarette smoking, current (or 3 months of past) use of
glucocorticoids, diagnosis of rheumatoid arthritis, con-
sumption of three or more units of alcohol daily, and
secondary osteoporosis. It can be used with or without the
addition of the bone mineral density derived T-score at the
femoral neck. For this analysis we defined the FRAX risk
factors as follows: previous adult fracture included any
fracture occurring after age 45; glucocorticoid use was
limited to current use only; and rheumatoid arthritis was not
included as a variable because of lack of physician
verification. “Secondary osteoporosis” was defined as
reported type 1 diabetes, menopause before the age of
45 years, ulcerative colitis, celiac disease, and use of
hypogonadism-inducing aromatase inhibitor medications
(anastrozole, letrozole, or exemestane). Bone density
testing may have been obtained in some subjects by their
primary physicians as part of routine care, but since it was
not performed as a component of the GLOW protocol, bone
density was not included in this analysis. For the
calculation of cumulative risk factors, weight less than
125 lb (57 kg) was used as the low weight variable.
Statistical analysis
Patients’ perceived risk of fracture was compared with the
presence of individual and combined numbers of risk
factors. To help ensure regional results were not influenced
by regional differences in age, regional proportions were
age standardized to reflect the age distribution of the entire
GLOW population, using four age groups: 55–64, 65–74,
75–84, and ≥85 years. For all other analyses three age
groups were used: 55–64, 65–74, and ≥75 years. All other
categorical variables are reported as raw frequencies. A
multiple logistic regression was used to estimate associa-
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tions between “much or a little higher” perception of
fracture risk and the seven individual FRAX risk factors;
estimates for number of FRAX factors and osteoporosis
diagnosis are from separate logistic regressions models. We
did not adjust for age, as the outcome is perceived risk
compared to women of the same age.
Results
Patient characteristics
A total of 60,393 patients from practices of 723 physicians
were enrolled in the study between October 2006 and
February 2008. Approximately 25,000 women came from
eight sites and 274 physician practices in Europe; 28,000
subjects were from 255 practices in the United States (US),
and almost 7000 patients came from 86 practices in Canada
and Australia. Among these women, 35% (20,345/58,434)
rated their risk of fracturing or breaking a bone to be “much
lower” or “a little lower” than that of women of the same
age, 46% (27,138/58,434) said their risk was “about the
same,” and 19% (10,951/58,434) rated their risk as “a little
higher” or “much higher” than women of the same age
(Table 1).
Subgroup analyses
When perceptions were viewed by age, the distributions
were similar for the three age groups (Table 1), with a
slightly greater proportion (21%, 3,164/10,951) of women
75 years and older considering themselves to be at higher
risk for fracture. Risk perception varied modestly by study
region, ranging from 14% (1,893/13,334) of women from
Northern Europe considering themselves to be at increased
risk, to 20% (2,220/10,887; 5,627/27,466) of those from
southern European and US sites.
Twenty-four percent (14,183/58,935) of women reported
having had a fracture since the age of 45, 17% (9,189/53,663)
reported a parental hip fracture, and 16% (9,436/57,900) had
weight <125 lb (Table 2). Secondary osteoporosis was self-
reported in 21% (12,403/57,974) of women, with menopause
before the age of 45 years the most prevalent (15%, 8,632/
59,399) of the four variables that comprised the diagnosis in
this analysis. Only 9% (5,484/59,816) of the women were
current cigarette smokers and fewer than 1% (290/59,813)
consumed more than 20 alcoholic drinks per week. When
combinations of risk factors were evaluated, 39% (23,772/
60,392) of women said they had no risk factors, 39%
(23,622/60,392) had a single risk factor, and 22% (12,998/
60,392) reported two or more risk factors.
Table 1 Perception of fracture risk compared with women of same age, by patient characteristic (n=60,393)
Group Perception of risk compared with women of same age (%)
Much or a little lower (n=20,345) About the same (n=27,138) Much or a little higher (n=10,951)
All women 35 (20,345/58,434) 46 (27,138/58,434) 19 (10,951/58,434)
Age group (years)
55 to 64 33 (7,374/22,632) 49 (11,192/22,632) 18 (4,066/22,632)
65 to 74 37 (7,574/20,672) 45 (9,377/20,672) 18 (3,721/20,672)
≥75 36 (5,397/15,130) 43 (6,569/15,130) 21 (3,164/15,130)
Regiona
Australia 37 (1,049/2,865) 46 (1,324/2,865) 17 (492/2,865)
Canada 33 (1,286/3,882) 48 (1,877/3,882) 19 (719/3,882)
Northern Europeb 33 (4,427/13,334) 53 (7,014/13,334) 14 (1,893/13,334)
(26–47) (38–61) (13–15)
(706/2,715–1,556/3,298) (1,244/3,298–1,678/2,715) (331/2,715–498/3,298)
Southern Europec 31 (3,359/10,887) 49 (5,308/10,887) 20 (2,220/10,887)
(19–37) (45–53) (15–28)
(518/2,828–1,227/3,320) (1,432/3,135–1,538/2,828) (509/3,320–772/2,828)
USA 37 (10,224/27,466) 42 (11,615/27,466) 20 (5,627/27,466)
(33–43) (39–44) (15–23)
(1,359/4,145–1,704/3,969) (1,180/3,066–1,832/4,145) (590/3,969–717/3,074)
a Age standardized to the GLOW population; range of regional site rates in brackets
b Belgium, Germany, The Netherlands, United Kingdom
c France, Italy, Spain
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Approximately 10% (2,332/22,953) of women who
reported none of the risk factors believed they were at
increased risk of fracture (Table 2). This number rose to
39% (701/1,797) among women who were current users of
glucocorticoids and to 36% (4,885/10,715) for those with a
history of previous fracture. However, even among the 22%
(12,998/60,392) of women who had two or more FRAX
risk factors, higher risk was perceived by just 33% (4,185/
12,612) of women.
Among the 25% (14,477/56,906) of women who were
without risk factors and without a diagnosis of osteoporosis
or use of a prescription osteoporosis treatment, presumably
conferring low risk for fracture, only 4.5% (633/14,066)
believed themselves to be at increased fracture risk
(Table 3). However, among women who reported having
been given a diagnosis of osteoporosis, perception of
increased risk for fracture was present in only 43%
(5,400/12,429). Similarly, only 41% (4,574/11,094) of
women who were on treatment with antiosteoporosis
medications believed that they were at heightened fracture
risk. Among women with more than one risk factor, a
reported diagnosis of osteoporosis, and who were currently
using antiosteoporosis medications, 62% (1,519/2,460)
viewed themselves as having an increased fracture risk.
In the multivariable model, five of the seven risk factors
showed statistically significant, independent associations
with subjects’ increased perception of risk (Table 4). The
strongest of these was previous fracture, with an odds ratio
of 3.3 (95% confidence interval [CI] 3.2–3.5), followed by
current use of cortisone or prednisone, and weight under
125 lb. Having been told by her doctor that she had
osteoporosis or osteopenia also increased the likelihood that
Table 2 Frequency of FRAXa risk factors and perceived fracture risk (n=60,393)
Risk factor Population (%) Perception of risk compared with women of same age (%)
Much or a little lower About the same Much or a little higher
No FRAX risk factors 39 (23,772/60,392) 42 (9,639/22,953) 48 (10,982/22,953) 10 (2,332/22,953)
Single FRAX risk factor
Weight <125 lb (57 kg) 16 (9,436/57,900) 32 (2,928/9,142) 42 (3,814/9,142) 26 (2,400/9,142)
Previous fracture after age 45 years 24 (14,183/58,935) 21 (2,903/13,760) 43 (5,972/13,760) 36 (4,885/13,760)
Parental hip fracture 17 (9,189/53,663) 28 (2,537/8,941) 46 (4,155/8,941) 25 (2,249/8,941)
Current smoker 9.2 (5,484/59,816) 31 (1,647/5,299) 50 (2,627/5,299) 19 (1,025/5,299)
Current cortisone/prednisone use 3.1 (1,835/59,191) 22 (400/1,797) 39 (696/1,797) 39 (701/1,797)
Secondary osteoporosis 21 (12,403/57,974) 31 (3,750/12,003) 45 (5,415/12,003) 24 (2,838/12,003)
Aromatase inhibitor 1.5 (863/58,975) 27 (224/834) 44 (369/834) 29 (241/834)
Celiac disease/colitis 2.6 (1,540/58,921) 26 (396/1,495) 42 (627/1,495) 32 (472/1,495)
Diabetes type 1 3.9 (2,341/59,434) 29 (646/2,235) 47 (1,040/2,235) 25 (549/2,235)
Menopause before age 45 15 (8,632/59,399) 33 (2,730/8,372) 45 (3,787/8,372) 22 (1,855/8,372)
Alcohol >20 drinks/week 0.5 (290/59,813) 34 (97/287) 46 (133/287) 20 (57/287)
Two or more FRAX risk factors 22 (12,998/60,392) 24 (2,994/12,612) 43 (5,433/12,612) 33 (4,185/12,612)
a FRAX risk factors are weight, history of fracture, parental hip fracture, cigarette smoking, current cortisone/prednisone use, secondary osteoporosis, and
alcohol use; secondary osteoporosis counts as a single risk factor
Table 3 Perceived fracture risk by medical diagnosis or treatment status (n=60,393)
Medical diagnosis or treatment Population (%) Perception of risk compared with women of same age (%)
As much as or
a little lower
About the same as As much as or
a little higher
No osteoporosis diagnosis, FRAX risk factors,
or osteoporosis prescription medications
25 (14,477/56,906) 48 (6,749/14,066) 48 (6,684/14,066) 4.5 (633/14,066)
On osteoporosis prescription medication 20 (11,365/58,107) 20 (2,207/11,094) 39 (4,313/11,094) 41 (4,574/11,094)
Diagnosed with osteoporosis 22 (12,753/56,994) 18 (2,247/12,429) 38 (4,782/12,429) 43 (5,400/12,429)
Diagnosed with osteopenia 16 (9,376/56,994) 28 (2,548/9,240) 48 (4,395/9,240) 25 (2,297/9,240)
Neither osteoporosis nor osteopenia diagnosis 61 (34,865/56,994) 43 (14,624/33,799) 49 (16,556/33,799) 7.8 (2,619/33,799)
Osteoporosis diagnosis, >1 FRAX risk factor
and osteoporosis medication
4.5 (2,506/55,258) 12 (286/2,460) 27 (655/2,460) 62 (1,519/2,460)
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a subject would see herself at increased risk for fracture.
Women with the diagnosis of osteoporosis were ten times
(95% CI 9.4–11) as likely, and those with osteopenia were
4.4 times as likely (95% CI 4.1–4.7), to perceive height-
ened fracture risk.
Discussion
In our large, international observational study, most women
generally considered their risk of future fracture to be lower
than or the same as that of other women their own age.
Findings across age groups and five geographic regions
consistently showed that about 20% of women rated
themselves at increased risk of fracture compared with
about 35% who indicated they considered themselves at
lower risk than their peers. However, among women who
reported individual or multiple characteristics that actually
put them at higher fracture risk than their peers, fewer than
50% recognized the increased risk. For example, only about
one third (4,885/13,760) of women with a previous fracture
after age 45—fracture being the most potent risk factor for
future fractures—viewed themselves to be at higher risk for
subsequent fractures than their peers, while 21% (2,903/
13,760) who had a prior fracture saw themselves as having
lower risk. History of parental hip fracture, another strong
predictor of future fractures, was also under-appreciated as
an important risk predictor: only 25% (2,249/8,941) of
women whose mother or father had broken a hip considered
themselves to be at higher risk of fracture. The highest
proportion of women who believed themselves to be at
increased risk based on individual FRAX risk factors (39%,
701/1,797) were those who reported currently taking
cortisone or prednisone.
Our data indicate that being given a diagnosis of either
osteoporosis or osteopenia is most likely to raise a woman’s
perception of risk (odds ratios of 10 and 4.4, respectively),
but even among women who had multiple FRAX risk
factors, a diagnosis of osteoporosis, and current use of an
osteoporosis prescription medication, only 62% (1,519/
2,460) believe themselves to be at increased risk.
Previous research on the topic of self-perceived risk of
osteoporosis and fracture is limited. Phillipov et al. [6]
reported on a community-based sample from the South
Australian Health Omnibus survey conducted in 1995.
They found that twice as many women considered
themselves to be at low as compared with high risk for
developing osteoporosis. Perceived risk was not increased
among women who actually had risk factors such as low body
mass index, family history of fracture, or current smoking and
was actually lower among older women. When Gerend et al.
[7] asked over 400 women from 63 community organiza-
tions in Phoenix, Arizona to rate their chances of developing
osteoporosis compared with other women of their own age,
almost four times as many thought they were at lower risk
than their peers. Giangregorio et al. [8] interviewed 127
patients (82% women) who had experienced a fragility
fracture in the preceding 2 years. Among this clearly high-
risk group, only 43% thought that they were at increased risk
of a future fracture.
Risk perception in GLOW for those taking medication
for osteoporosis might be interpreted in two ways. Women
could respond to the question using their assessment of
premedication risk or considering on-treatment risk. When
we examined patterns of risk perception for the subset of
women on antiosteoporosis treatment, 41% (4,574/11,094)
responded that their risk of fracture was greater than that of
their peers, suggesting that premedication risk was being
considered.
The reason why some women with risk factors fail to see
themselves at heightened likelihood of fracture may be
because they are unaware that characteristics such as prior
fracture, parental history of hip fracture, low weight,
smoking, early menopause, and high intake of alcohol
contribute to risk. Support for such lack of recognition of
well-established risk factors comes from Satterfield et al.,
who surveyed 400 US women aged 60 to 80 years in a
random-digit dial telephone survey [14]. They found that
women correctly identified risk related to smoking, exer-
cise, calcium intake, and family history of fracture more
Table 4 Associations of baseline risk factors for fractures with
perceived higher-than-average fracture risk (compared with women of
the same age; n=45,125 women with complete information on risk
factors)
Risk factor Odds ratio 95% Confidence interval
Weighta <125 lb (57 kg) 1.8 1.7 to 1.9
Previous fracture 3.3 3.2 to 3.5
Parental hip fracture 1.6 1.5 to 1.7
Current smoker 1.0 0.9 to 1.1
Current glucocorticoid use 2.6 2.3 to 2.9
Secondary osteoporosisb 1.5 1.4 to 1.6
Alcohol >20 drinks/week 1.1 0.8 to 1.6
Number of FRAX risk factors (vs none)
1 2.1 1.9 to 2.2
2 or more 4.5 4.3 to 4.8
Osteoporosis diagnosis (vs neither)
Osteopenia 4.4 4.1 to 4.7
Osteoporosis 10 9.4 to 11
a Estimates for weight, previous fracture, parental hip fracture, current
smoker, current glucocorticoid use, secondary osteoporosis, and alcohol
use are from a multiple logistic model with these seven risk factors (c-
index 0.68); other estimates are unadjusted
b Aromatase inhibitor treatment, celiac disease/colitis, diabetes type 1, and
menopause before age 45
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than 60% of the time, but identified risks associated with
early menopause, long-term steroid use, being thin, and use
of alcohol less than 50% of the time. In the multivariable
model reported here, neither smoking nor heavy alcohol use
appeared significantly related to a perception of higher-
than-average fracture risk. Furthermore, although signifi-
cant odds ratios in our models indicate that some women
appreciated the added risk conferred by five of the seven
FRAX risk factors, the magnitude of these ratios (in the
range of 1.5–3.4) suggest that the association is not large.
Even having been given the “diagnosis of osteoporosis” or
“currently taking antiosteoporosis medication” only raised
risk awareness to levels of 43% (5,400/12,429) and 41%
(4,574/11,094), respectively.
The lack of accurate perception of fracture risk has
adverse implications for successful fracture-prevention
activities. Motivation for patients to seek and follow
treatment is related to perceived susceptibility to a disease
[15]. Cline et al. [16] reported that, among almost 1,000
women aged 45 and older residing in a Minnesota
community, higher perception of susceptibility to osteopo-
rosis was significantly associated with use of osteoporosis
medications. Responsibility for accurately conveying risk
for fracture to patients at increased risk will require careful
explanation by the woman’s physician, and this may be
enhanced by the availability of risk assessment tools such
as FRAX, which allows patients and physicians to work
together to understand which patients have a high enough
risk to require medication to lower that risk and which
patients do not. It is also clear from the US Surgeon
General’s Report on Bone Health and Osteoporosis [17]
that public health efforts to educate patients about risk
factors as well as patients taking personal responsibility for
their own health issues will be needed to help those at risk
recognize their susceptibility to problems such as future
fractures.
Strengths and limitations
Our intention in GLOW was to include subjects who were
broadly representative of women aged 55 and older by
attempting to enlist all women in this age group who were
active patients in each physician’s practice. As a non-
randomized, observational, practice-based study, however,
GLOW is subject to biases in both the selection of
physicians and the sampling and recruitment of patients. It
is possible that participants would have greater interest in
bone health issues and seek information, screening, and
treatment more actively. Physicians who agreed to partic-
ipate may not be representative of all physicians in a given
area with respect to osteoporosis recognition and manage-
ment. As increasing age is acknowledged to be the single
most predictive risk of fracture, we attempted to mitigate its
confounding influence by asking women to rate their
personal risk in comparison to women of their own age.
This strategy appeared to operate successfully, as the age-
stratified analyses shown in Table 1 indicated that distribu-
tions of perceived risk were similar among women across
age groups.
Possible confusion among subjects between rheumatoid
and other types of arthritis prompted us to drop the
characteristic from our analysis. We also considered only
current use of the glucocorticoids prednisone and cortisone
as a risk factor where FRAX considers “ever use” a risk.
Reports that have critically assessed increased susceptibility
to fracture risk and the timing of glucocorticoid use suggest
that current use is the most important predictor and that
once use is discontinued, fracture susceptibility returns to
baseline levels [18]. Aromatase inhibitors, while not
specifically suggested as risk factors in the FRAX algo-
rithm, were included because of their antiestrogenic
properties and their association with bone loss and elevated
risk of fractures in postmenopausal women [19].
Conclusion
Our data document, in a population of over 60,000
postmenopausal women from ten countries in North
America and Europe, as well as Australia, that there is a
consistent under-appreciation of personal risk factors for
osteoporosis and fracture. Tools for diagnosis and risk
assessment are widely available, as are safe and effective
treatments when indicated, but if women fail to appreciate
their own risks there will inevitably be a barrier to them
receiving appropriate assessment and management. Im-
proved education of both physicians and postmenopausal
women about osteoporosis risk factors is needed.
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